Johnson & Johnson (NYSE:JNJ) is CapWealth Advisors LLC’s 7th Largest Position

CapWealth Advisors LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 23.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 145,884 shares of the company’s stock after purchasing an additional 27,578 shares during the period. Johnson & Johnson accounts for approximately 3.3% of CapWealth Advisors LLC’s portfolio, making the stock its 7th largest position. CapWealth Advisors LLC’s holdings in Johnson & Johnson were worth $18,826,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after acquiring an additional 3,235,861 shares during the period. Vanguard Group Inc lifted its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after acquiring an additional 3,235,861 shares during the period. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 1.9% during the 4th quarter. BlackRock Inc. now owns 182,903,344 shares of the company’s stock valued at $23,603,679,000 after acquiring an additional 3,486,924 shares during the period. Oregon Public Employees Retirement Fund lifted its position in shares of Johnson & Johnson by 11,576.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 74,757,633 shares of the company’s stock valued at $579,000 after acquiring an additional 74,117,373 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Johnson & Johnson by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 36,364,874 shares of the company’s stock valued at $4,685,372,000 after acquiring an additional 2,741,351 shares during the period. Hedge funds and other institutional investors own 66.90% of the company’s stock.

JNJ opened at $140.71 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.13 and a current ratio of 1.44. Johnson & Johnson has a 1-year low of $120.11 and a 1-year high of $148.99. The firm has a market cap of $371.12 billion, a price-to-earnings ratio of 17.20, a price-to-earnings-growth ratio of 2.42 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The firm had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter in the prior year, the company posted $2.06 earnings per share. The business’s revenue was up .1% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th were issued a dividend of $0.95 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date was Friday, May 24th. This represents a $3.80 annualized dividend and a yield of 2.70%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

In other Johnson & Johnson news, Director Marillyn A. Hewson acquired 3,000 shares of the stock in a transaction on Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $419,040. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.23% of the company’s stock.

JNJ has been the topic of a number of research reports. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 17th. Citigroup boosted their target price on shares of Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research report on Monday, February 25th. BMO Capital Markets boosted their target price on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, May 28th. They set a “buy” rating on the stock. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 target price on the stock in a research report on Wednesday, March 27th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus price target of $147.30.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (NYSE:JNJ) is CapWealth Advisors LLC’s 7th Largest Position” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2019/06/14/johnson-johnson-nysejnj-is-capwealth-advisors-llcs-7th-largest-position.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Should you buy a closed-end mutual fund?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.